TY - JOUR AU - McElroy, Anita AU - Shrivastava-Ranjan, Punya AU - Harmon, Jessica AU - Martines, Roosecelis AU - Silva-Flannery, Luciana AU - Flietstra, Timothy AU - Kraft, Colleen AU - Mehta, Aneesh AU - Lyon, G. Marshall AU - Varkey, Jay AU - Ribner, Bruce AU - Nichol, Stuart AU - Zaki, Sherif AU - Spiropoulou, Christina T1 - Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans T2 - Emerging Infectious Disease journal PY - 2019 VL - 25 IS - 2 SP - 290 SN - 1080-6059 AB - Ebola virus disease (EVD) is associated with elevated cytokine levels, and hypercytokinemia is more pronounced in fatal cases. This type of hyperinflammatory state is reminiscent of 2 rheumatologic disorders known as macrophage activation syndrome and hemophagocytic lymphohistiocytosis, which are characterized by macrophage and T-cell activation. An evaluation of 2 cohorts of patients with EVD revealed that a marker of macrophage activation (sCD163) but not T-cell activation (sCD25) was associated with severe and fatal EVD. Furthermore, substantial immunoreactivity of host tissues to a CD163-specific antibody, predominantly in areas of extensive immunostaining for Ebola virus antigens, was observed in fatal cases. These data suggest that host macrophage activation contributes to EVD pathogenesis and that directed antiinflammatory therapies could be beneficial in the treatment of EVD. KW - Ebola KW - inflammation KW - macrophage KW - MAS KW - HLH KW - Ebola virus KW - Ebola virus disease KW - sCD163 KW - activation marker KW - severe disease KW - humans KW - viruses KW - macrophage activation syndrome KW - hemophagocytic lymphohistiocytosis KW - sCD25 KW - CD163 KW - T cells KW - hyperferritinemia KW - hypertriglyceridemia KW - zoonoses DO - 10.3201/eid2502.181326 UR - https://wwwnc.cdc.gov/eid/article/25/2/18-1326_article ER - End of Reference